Another study consisting of patients with solid and hematologic cancers illustrated that the patients with hematologic cancers were 1.67 times more likely to present aCL positivity than the patients with solid cancers. This evidence concerns the gene ACLY and hematopoietic and lymphoid cell neoplasm.